NCT01381835View on ClinicalTrials.gov

TMC435-TiDP16-C126 - Trial to Investigate the Effect of Severe Renal Impairment on the Pharmacokinetics and Safety of TMC435

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 31, 2011

Study Completion Date

January 31, 2012

Conditions
Hepatitis C Virus
Interventions
DRUG

TMC435

150 mg capsule once daily for 7 days

Trial Locations (1)

Unknown

Prague

All Listed Sponsors
lead

Tibotec Pharmaceuticals, Ireland

INDUSTRY

NCT01381835 - TMC435-TiDP16-C126 - Trial to Investigate the Effect of Severe Renal Impairment on the Pharmacokinetics and Safety of TMC435 | Biotech Hunter | Biotech Hunter